Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux Obtains CE Mark for VIDAS 3, Plans to Pursue US FDA Approval

Premium

BioMérieux said that its VIDAS 3 immunoassay platform has received an EU CE mark, making it commercially available in Europe and other countries recognizing the CE marking.

In a statement, François Lacoste, corporate vice president of BioMérieux's immunoassay unit, said the company now plans to pursue regulatory approval for the platform in other countries – the US and China, in particular.

The VIDAS 3 is the latest in BioMérieux's VIDAS line and, the company said, offers enhanced automation, improved traceability, and new software features, as well as a quality control program that is in compliance with laboratory certification standards.

Using the same reagents as previous VIDAS instruments, the device currently offers tests for 99 clinical parameters.

According to BioMérieux, the VIDAS line has the largest installed base of automated immunoassay systems in the world, with more than 27,000 instruments in clinical labs. The company claims that it has received roughly 200 intentions to purchase the new instrument based on recent conference demonstrations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.